In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes

In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes

Source: 
Endpoints
snippet: 

Mike Grey doesn’t have any time to waste. Having regained control of two liver disease drugs from Shire and positioned them for pivotal studies — five years after first handing them off in a deal to sell Lumena, where he was CEO — Grey is steering Mirum straight into an IPO with a $86 million ask.